Pfizer (NYSE: PFE) EVP Payal Sahni awarded 108,268 stock appreciation rights

Rhea-AI Filing Summary

SAHNI PAYAL reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Executive Vice President Payal Sahni received a grant of 108,268 stock appreciation rights. These derivative awards were granted at a price of $0.00 per right and are scheduled to be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, subject to vesting requirements.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SAHNI PAYAL

Role Executive Vice President

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	108,268	$0.00	--

Holdings After Transaction: Stock Appreciation Rights — 108,268 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAHNI PAYAL

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		108,268		03/03/2031(1)	03/03/2031(1)	Common Stock	108,268	$0.0000	108,268	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for Payal Sahni	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) disclose for Payal Sahni?

Pfizer disclosed that Executive Vice President Payal Sahni received a grant of 108,268 stock appreciation rights. These derivative awards were granted at $0.00 per right and will be settled in Pfizer common stock after vesting conditions are met.

How many stock appreciation rights were granted to Pfizer EVP Payal Sahni?

Pfizer’s Executive Vice President Payal Sahni was granted 108,268 stock appreciation rights. This entire amount remains credited to her following the transaction, reflecting a single award of derivative securities linked to Pfizer common stock.

When will Payal Sahni’s Pfizer stock appreciation rights be settled?

The stock appreciation rights granted to Payal Sahni will be settled in Pfizer common stock on the fifth anniversary of the grant date. Settlement depends on meeting the vesting requirements attached to the award.

What are the key terms of Payal Sahni’s Pfizer stock appreciation rights award?

The award to Payal Sahni consists of 108,268 stock appreciation rights granted at $0.00 per right. They are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Is Payal Sahni’s Pfizer stock appreciation rights grant an acquisition or a sale?

The transaction is classified as an acquisition of derivative securities. Payal Sahni received a grant or award of 108,268 stock appreciation rights, rather than selling or disposing of Pfizer-related securities in the market.

Does Payal Sahni hold these Pfizer stock appreciation rights directly or indirectly?

The filing indicates direct ownership of the stock appreciation rights by Payal Sahni. The total of 108,268 derivative securities is reported as directly owned following the grant transaction.